MA38814B2 - Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs - Google Patents
Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifsInfo
- Publication number
- MA38814B2 MA38814B2 MA38814A MA38814A MA38814B2 MA 38814 B2 MA38814 B2 MA 38814B2 MA 38814 A MA38814 A MA 38814A MA 38814 A MA38814 A MA 38814A MA 38814 B2 MA38814 B2 MA 38814B2
- Authority
- MA
- Morocco
- Prior art keywords
- antagonist
- proliferative disorders
- treatment
- gitr agonist
- gitr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne des méthodes de traitement de troubles prolifératifs. En particulier, l'invention concerne une polythérapie à l'aide d'un agoniste gitr et d'un antagoniste pd-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361867976P | 2013-08-20 | 2013-08-20 | |
PCT/US2014/051402 WO2015026684A1 (fr) | 2013-08-20 | 2014-08-18 | Modulation d'immunité tumorale |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38814A1 MA38814A1 (fr) | 2018-01-31 |
MA38814B2 true MA38814B2 (fr) | 2019-12-31 |
Family
ID=51493040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38814A MA38814B2 (fr) | 2013-08-20 | 2014-08-18 | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs |
Country Status (43)
Families Citing this family (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
LT3023438T (lt) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
EP3049442A4 (fr) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
RS59480B1 (sr) | 2013-12-12 | 2019-12-31 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena |
EP3083692B1 (fr) * | 2013-12-17 | 2020-02-19 | F.Hoffmann-La Roche Ag | Méthode de traitement des cancers utilisant des antagonists se liant à l'axe pd-1 et des taxanes |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
JP6903432B2 (ja) | 2014-03-12 | 2021-07-14 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Cnsの疾患および傷害を処置するために全身性調節性t細胞のレベルまたは活性を低下させること |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
WO2015157636A1 (fr) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Expansion améliorée des lymphocytes infiltrants des tumeurs pour thérapie cellulaire adoptive |
MA47849A (fr) | 2014-05-28 | 2020-01-29 | Agenus Inc | Anticorps anti-gitr et leurs procédés d'utilisation |
EA037006B1 (ru) | 2014-06-06 | 2021-01-26 | Бристол-Майерс Сквибб Компани | Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CU20170052A7 (es) | 2014-10-14 | 2017-11-07 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 |
CA2967426A1 (fr) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Anticorps heterodimeriques se liant a l'antigene cd3 et a un antigene tumoral |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
EP3233918A1 (fr) | 2014-12-19 | 2017-10-25 | Novartis AG | Polythérapies |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
EP3304079B1 (fr) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anticorps anti-gitr pour le diagnostic du cancer |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
MX2017016353A (es) | 2015-06-17 | 2018-05-02 | Genentech Inc | Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos. |
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
EP3325512B1 (fr) | 2015-07-23 | 2023-09-06 | Inhibrx, Inc. | Protéines hybrides multivalentes et multispécifiques se liant à gitr |
SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
JP6840127B2 (ja) | 2015-07-29 | 2021-03-10 | ノバルティス アーゲー | がんの治療における抗pd−1抗体および抗m−csf抗体の併用 |
EP3316902A1 (fr) | 2015-07-29 | 2018-05-09 | Novartis AG | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
KR20180034588A (ko) | 2015-07-30 | 2018-04-04 | 마크로제닉스, 인크. | Pd-1-결합 분자 및 그것의 사용 방법 |
EA201890630A1 (ru) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | Антитела против pd-1 и способы их применения |
US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合 |
IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
CR20180318A (es) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas |
CA3007671A1 (fr) | 2015-12-17 | 2017-06-22 | Novartis Ag | Molecules d'anticorps anti-pd-1 et leurs utilisations |
KR20180100224A (ko) | 2016-01-11 | 2018-09-07 | 노바르티스 아게 | 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질 |
MA43814A (fr) | 2016-03-08 | 2018-11-28 | Janssen Biotech Inc | Anticorps anti-gitr, méthodes et utilisations |
TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
EP3458053B1 (fr) | 2016-05-20 | 2021-12-08 | Biohaven Pharmaceutical Holding Company Ltd. | Utilisation du riluzole, de promédicaments du riluzole ou d'analogues du riluzole avec des immunothérapies pour traiter les cancers |
CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
AU2017278193B9 (en) * | 2016-06-10 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
TWI784957B (zh) | 2016-06-20 | 2022-12-01 | 英商克馬伯有限公司 | 免疫細胞介素 |
US20190263919A1 (en) | 2016-07-01 | 2019-08-29 | Five Prime Therapeutics, Inc. | Combined anti tumor therapy with a gitr agonist and cpg |
EP3507367A4 (fr) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
WO2018018039A2 (fr) | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Anticorps dirigés contre le récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs procédés d'utilisation |
TN2019000081A1 (en) | 2016-09-14 | 2020-07-15 | Beijing hanmi pharm co ltd | Antibody specifically binding to pd-1 and functional fragment thereof |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
CA3041340A1 (fr) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anticorps anti-ox40, anticorps anti-gitr, et leurs procedes d'utilisation |
MA50056A (fr) | 2017-03-31 | 2020-02-05 | Bristol Myers Squibb Co | Procédés de traitement de tumeur |
WO2018185618A1 (fr) | 2017-04-03 | 2018-10-11 | Novartis Ag | Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
KR102376863B1 (ko) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | 메소텔린 결합 단백질 |
CN110869392A (zh) * | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
WO2018223004A1 (fr) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Anticorps bispécifiques se liant à cd20 et cd3 |
CA3065929A1 (fr) | 2017-06-01 | 2018-12-06 | Michael Wayne SAVILLE | Anticorps bispecifiques liant cd123 cd3 |
WO2018229715A1 (fr) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants |
WO2018234879A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | UTILISATION D'ANTICORPS DE LIAISON IL-1β DANS LE TRAITEMENT DU CANCER |
WO2018235056A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer |
WO2018237173A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes |
JP7433910B2 (ja) | 2017-06-22 | 2024-02-20 | ノバルティス アーゲー | Cd73に対する抗体分子及びその使用 |
WO2019006007A1 (fr) | 2017-06-27 | 2019-01-03 | Novartis Ag | Régimes posologiques pour anticorps anti-tim3 et leurs utilisations |
JP2020527572A (ja) | 2017-07-20 | 2020-09-10 | ノバルティス アーゲー | 抗lag−3抗体の投薬量レジメンおよびその使用 |
CN111247169A (zh) | 2017-10-15 | 2020-06-05 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
WO2019081983A1 (fr) | 2017-10-25 | 2019-05-02 | Novartis Ag | Anticorps ciblant cd32b et leurs procédés d'utilisation |
JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
WO2019184909A1 (fr) | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | Nouvelle molécule d'anticorps, son procédé de préparation et son utilisation |
CN110305210B (zh) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
EP3801766A1 (fr) | 2018-05-31 | 2021-04-14 | Novartis AG | Anticorps contre l'hépatite b |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
KR20210016426A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Cd123 및 cd3에 결합하는 이중특이적 항체의 투약 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
RS64759B1 (sr) | 2018-07-10 | 2023-11-30 | Novartis Ag | 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-dion derivati i njihova primena u lečenju bolesti zavisnih od cink prsta 2 (ikzf2) iz porodice ikaros |
WO2020021465A1 (fr) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Procédé de traitement de tumeurs neuroendocrines |
WO2020053742A2 (fr) | 2018-09-10 | 2020-03-19 | Novartis Ag | Anticorps peptidiques anti-hla-vhb |
SG11202101787XA (en) | 2018-09-20 | 2021-04-29 | Iovance Biotherapeutics Inc | Expansion of tils from cryopreserved tumor samples |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
CA3115102A1 (fr) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-npr1 et leurs utilisations |
EP3873532A1 (fr) | 2018-10-31 | 2021-09-08 | Novartis AG | Conjugué médicament-anticorps anti-dc-sign |
CA3115545A1 (fr) * | 2018-11-13 | 2020-05-22 | Jn Biosciences Llc | Anticorps bispecifiques pour l'activation de cellules immunitaires |
AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
KR20210107730A (ko) | 2018-12-21 | 2021-09-01 | 노파르티스 아게 | 골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도 |
KR20210108422A (ko) | 2018-12-21 | 2021-09-02 | 노파르티스 아게 | IL-1β 결합 항체의 용도 |
US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
WO2020128637A1 (fr) | 2018-12-21 | 2020-06-25 | Novartis Ag | UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H |
AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
EP3725370A1 (fr) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Anticorps anti-pd-l1 modifiés et procédés et utilisations pour le traitement d'une maladie neurodégénérative |
WO2020243568A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
MX2022004769A (es) | 2019-10-21 | 2022-05-16 | Novartis Ag | Inhibidores de tim-3 y sus usos. |
CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
WO2021123996A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Utilisations d'anticorps anti-tgf-bêtas et inhibiteurs de point de contrôle pour le traitement des maladies prolifératives |
CN114980902A (zh) | 2020-01-17 | 2022-08-30 | 诺华股份有限公司 | 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合 |
US11862306B1 (en) | 2020-02-07 | 2024-01-02 | Cvs Pharmacy, Inc. | Customer health activity based system for secure communication and presentation of health information |
WO2021171264A1 (fr) | 2020-02-28 | 2021-09-02 | Novartis Ag | Dosage d'un anticorps bispécifique qui se lie à cd123 et cd3 |
BR112022017156A2 (pt) | 2020-03-06 | 2022-11-08 | Regeneron Pharma | Anticorpo isolado ou fragmento de ligação, molécula polinucleotídica isolada, vetor, célula hospedeira isolada, composição farmacêutica, método de tratamento de câncer, e, uso de um anticorpo |
EP4165169A1 (fr) | 2020-06-11 | 2023-04-19 | Novartis AG | Inhibiteurs de zbtb32 et leurs utilisations |
WO2021260528A1 (fr) | 2020-06-23 | 2021-12-30 | Novartis Ag | Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione |
WO2022003693A1 (fr) * | 2020-07-02 | 2022-01-06 | Biolojic Design Ltd. | Anticorps anti-récepteur du facteur de nécrose tumorale (tnfr2) et leurs utilisations |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
WO2022043557A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
WO2022043558A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル-マイヤーズ スクイブ カンパニー | Pd1/pd-l1抗体の皮下投与 |
CN116761622A (zh) * | 2021-01-08 | 2023-09-15 | 苏州丁孚靶点生物技术有限公司 | 药物产品及其用途 |
EP4314068A1 (fr) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Anticorps dirigés contre un cdcp1 clivé et leurs utilisations |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
CA2006408A1 (fr) * | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Anticorps monoclaux bispecifiques, production et utilisation |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US6326482B1 (en) | 1999-04-23 | 2001-12-04 | Genentech, Inc. | SH2 domain-containing peptides |
MXPA01005515A (es) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Anticuerpos humanizados para gamma-interferon. |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
US7670604B2 (en) | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
CA2525717A1 (fr) | 2003-05-23 | 2004-12-09 | Wyeth | Ligand du gitr et molecules et anticorps lies au ligand du gitr et leurs utilisations |
PE20090047A1 (es) | 2003-11-10 | 2009-01-26 | Schering Corp | Anticuerpo recombinante humanizado anti-interleuquina 10 |
WO2005120571A2 (fr) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation |
ATE508204T1 (de) | 2004-07-15 | 2011-05-15 | Univ Wien Tech | Verfahren für den nachweis von fusarium graminearum |
EP1866339B8 (fr) * | 2005-03-25 | 2021-12-01 | GITR, Inc. | Molecules de liaison gitr et leurs utilisations |
LT2439273T (lt) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
CN105330741B (zh) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用 |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
NO2344540T3 (fr) | 2008-10-02 | 2018-04-28 | ||
SI2376535T1 (sl) | 2008-12-09 | 2017-07-31 | F. Hoffmann-La Roche Ag | Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t |
LT3023438T (lt) * | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antikūnai |
EP2473519A4 (fr) * | 2009-09-03 | 2013-04-10 | Univ Illinois | Traitement de maladies induites par des exotoxines bactériennes |
US20110300186A1 (en) | 2010-04-14 | 2011-12-08 | Battelle Memorial Institute | Functionalized Nano- and Micro-materials for Medical Therapies |
JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体 |
LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
TW201840336A (zh) | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
US20130071403A1 (en) * | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
EP2771031B1 (fr) | 2011-10-28 | 2018-04-18 | Prothena Biosciences Limited | Anticorps humanisés qui reconnaissent l'alpha-synucléine |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
AU2017278193B9 (en) | 2016-06-10 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
-
2014
- 2014-08-11 AR ARP140103008A patent/AR097306A1/es unknown
- 2014-08-15 TW TW103128185A patent/TWI660737B/zh not_active IP Right Cessation
- 2014-08-18 AP AP2016009073A patent/AP2016009073A0/xx unknown
- 2014-08-18 HU HUE14761460A patent/HUE052967T2/hu unknown
- 2014-08-18 UA UAA201602684A patent/UA118453C2/uk unknown
- 2014-08-18 DK DK14761460.6T patent/DK3036256T3/da active
- 2014-08-18 WO PCT/US2014/051402 patent/WO2015026684A1/fr active Application Filing
- 2014-08-18 RS RS20201551A patent/RS61228B1/sr unknown
- 2014-08-18 MD MDA20160024A patent/MD20160024A2/ro not_active Application Discontinuation
- 2014-08-18 MA MA38814A patent/MA38814B2/fr unknown
- 2014-08-18 SG SG10201800389YA patent/SG10201800389YA/en unknown
- 2014-08-18 CA CA2921561A patent/CA2921561C/fr not_active Expired - Fee Related
- 2014-08-18 JP JP2016536340A patent/JP6383419B2/ja not_active Expired - Fee Related
- 2014-08-18 ES ES14761460T patent/ES2835727T3/es active Active
- 2014-08-18 EP EP14761460.6A patent/EP3036256B1/fr not_active Revoked
- 2014-08-18 TN TN2016000041A patent/TN2016000041A1/en unknown
- 2014-08-18 GE GEAP201414103A patent/GEP20186905B/en unknown
- 2014-08-18 MX MX2016002271A patent/MX360789B/es active IP Right Grant
- 2014-08-18 MY MYPI2016000312A patent/MY187075A/en unknown
- 2014-08-18 AU AU2014309163A patent/AU2014309163A1/en not_active Abandoned
- 2014-08-18 SG SG11201600990VA patent/SG11201600990VA/en unknown
- 2014-08-18 BR BR112016003394A patent/BR112016003394A2/pt not_active Application Discontinuation
- 2014-08-18 LT LTEP14761460.6T patent/LT3036256T/lt unknown
- 2014-08-18 KR KR1020187009892A patent/KR20180038081A/ko not_active Application Discontinuation
- 2014-08-18 SI SI201431723T patent/SI3036256T1/sl unknown
- 2014-08-18 EA EA201690429A patent/EA201690429A1/ru unknown
- 2014-08-18 PL PL14761460.6T patent/PL3036256T3/pl unknown
- 2014-08-18 CN CN201480046383.4A patent/CN105492463B/zh not_active Expired - Fee Related
- 2014-08-18 KR KR1020167004045A patent/KR101979070B1/ko active IP Right Grant
- 2014-08-18 PE PE2016000270A patent/PE20160225A1/es unknown
- 2014-08-18 US US14/912,733 patent/US10188729B2/en active Active
- 2014-08-18 PT PT147614606T patent/PT3036256T/pt unknown
- 2014-08-18 EP EP20190848.0A patent/EP3770175A3/fr not_active Withdrawn
- 2014-08-20 JO JOP/2014/0253A patent/JO3553B1/ar active
-
2016
- 2016-02-04 IL IL243986A patent/IL243986B/en active IP Right Grant
- 2016-02-05 NI NI201600025A patent/NI201600025A/es unknown
- 2016-02-12 DO DO2016000049A patent/DOP2016000049A/es unknown
- 2016-02-15 PH PH12016500309A patent/PH12016500309A1/en unknown
- 2016-02-16 CL CL2016000354A patent/CL2016000354A1/es unknown
- 2016-02-19 GT GT201600036A patent/GT201600036A/es unknown
- 2016-02-19 CR CR20160086A patent/CR20160086A/es unknown
- 2016-02-19 SV SV2016005158A patent/SV2016005158A/es unknown
- 2016-03-18 EC ECIEPI201611533A patent/ECSP16011533A/es unknown
- 2016-07-08 HK HK16108016.5A patent/HK1219960A1/zh unknown
-
2017
- 2017-07-06 JP JP2017132379A patent/JP2018008953A/ja not_active Withdrawn
- 2017-09-06 AU AU2017225039A patent/AU2017225039B2/en not_active Ceased
- 2017-12-25 JP JP2017247383A patent/JP2018070648A/ja not_active Withdrawn
-
2018
- 2018-03-20 US US15/926,035 patent/US10994008B2/en active Active
-
2020
- 2020-12-11 CY CY20201101173T patent/CY1123647T1/el unknown
- 2020-12-21 HR HRP20202042TT patent/HRP20202042T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA41013A (fr) | Compositions comprenant des souches bactériennes | |
NZ737399A (en) | Ccr2 modulators | |
MA40035A (fr) | Molécules d'anticorps de pd-l1 et leurs utilisations | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
TN2016000272A1 (en) | Antibody molecules to pd-1 and uses thereof. | |
EA201790575A1 (ru) | Триазолопиразиноны в качестве ингибиторов pde1 | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
FR2975600B1 (fr) | Agents pour le traitement de tumeurs | |
MA41977B1 (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
MX2017003646A (es) | Compuestos y metodos. | |
MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
MA44747A (fr) | Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique | |
MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 | |
NZ724799A (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
EA201691335A1 (ru) | Гексагидрофуропирролы в качестве ингибиторов pde1 | |
EA201491522A1 (ru) | Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина | |
MA39336A1 (fr) | Molécules d'anticorps anti-lag-3 et leurs utilisations |